MGI kept by JMP at market outperform

MGI Pharma Inc. was reiterated by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $33 per share following a survey of experienced hematologists that showed a high level of awareness and enthusiasm for its drug Dacogen in the treatment of advanced myelodysplastic syndrome. MGI Pharma shares Tuesday were down $0.42, or 1.58%, at $26.17 on volume of 926,437 shares versus the three-month running average of 1,302,620 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.